Evidence map›Paper›PMID 19641653›Full record

ArticleExperimental and clinical cardiology2003

Amyocarditic coxsackievirus B3 causes myocarditis in immunocompromised mice.

Hitoshi Takada, Chiharu Kishimoto, Masahiko Kurokawa, Yuji Hiraoka

Abstract read
In one paragraph

Article in Experimental and clinical cardiology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hitoshi TakadaThe Second Department of Internal Medicine; and.
Chiharu Kishimoto
Masahiko Kurokawa
Yuji Hiraoka

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study, we investigated the role of the immune status of the host in the pathogenesis and development of coxsackievirus B3 myocarditis. We compared the disease expression in myocarditic coxsackievirus B3 (CB3M)-infected BALB/c wild-type mice and severe combined immunodeficient (SCID) mice and in amyocarditic coxsackievirus B3 (CB3O)-infected BALB/c wild-type mice untreated or treated with immunosuppressive agents and SCID mice. There were no differences in viral growth in vitro between CB3M and CB3O. Severe myocarditis developed in CB3M-infected wild-type and SCID mice, CB3O-infected SCID mice and CB3O-infected wild-type mice with total immunosuppression. However, myocarditis was not induced in CB3O-infected wild-type mice untreated and treated with partial immunosuppression. There were no changes in myocardial virus titres among these groups of mice. In addition, myocarditis was induced in CB3O-infected wild-type mice treated with Thy 1.2 (pan T) or Lyt 2 (CD8) antibody but not in those mice treated with L3T4 (CD4) antibody. Thus, the CB3O variant did not induce myocarditis in wild-type mice associated with the induction of the CD8(+) lymphocyte subset but was shown to have the genetic capability to induce myocarditis if the host was in an almost total immunosuppressive or CD8-depleted state. The results suggest that induction of myocarditis by the amyocarditic strain of coxsackievirus B3 may occur and partially depends on the immune status of the host, and that myocarditis is due in part to an immunopathogenic mechanism.

Indexed as

Amyocarditic strainCoxsackievirus B3Severe combined immunodeficient mice

Identifiers

PMID19641653
PMCPMC2716202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.